Description
MOXIBOLIC CV 625 MG (Moxifloxacin + Clavulanic Acid)
Indications
MOXIBOLIC CV 625 MG is indicated for the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections caused by susceptible strains of bacteria.
Mechanism of Action
Moxifloxacin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription. Clavulanic acid is a beta-lactamase inhibitor that protects moxifloxacin from degradation by beta-lactamase enzymes produced by resistant bacteria.
Pharmacological Properties
MOXIBOLIC CV 625 MG exhibits broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria. It is well-absorbed after oral administration and has a long half-life, allowing for once-daily dosing.
Contraindications
MOXIBOLIC CV 625 MG is contraindicated in patients with a known hypersensitivity to moxifloxacin, clavulanic acid, or any other components of the formulation. It should not be used in patients with a history of tendon disorders related to fluoroquinolone use.
Side Effects
Common side effects may include nausea, diarrhea, headache, dizziness, and rash. Serious side effects can include tendon rupture, QT prolongation, and severe allergic reactions.
Dosage and Administration
The recommended dosage for adults is one tablet (625 mg) taken orally once daily, with or without food. Dosage adjustments may be necessary for patients with renal impairment.
Interactions
MOXIBOLIC CV 625 MG may interact with anticoagulants, antidiabetic medications, and other drugs that prolong the QT interval. Patients should inform their healthcare provider of all medications they are taking.
Precautions
Patients should be monitored for signs of tendon pain or swelling. Caution is advised in patients with a history of seizures, liver disease, or those who are pregnant or breastfeeding.
Clinical Studies
Clinical studies have demonstrated the efficacy of MOXIBOLIC CV 625 MG in treating various infections, showing significant improvement in clinical outcomes compared to placebo and other antibiotics.
Conclusion
MOXIBOLIC CV 625 MG is an effective treatment option for a range of bacterial infections, combining the potent antibacterial activity of moxifloxacin with the protective effects of clavulanic acid against resistance.
IMPORTANT
Patients should take MOXIBOLIC CV 625 MG exactly as prescribed and report any unusual symptoms or side effects to their healthcare provider immediately. This medication should not be shared with others, and it is essential to complete the full course of therapy to prevent the development of antibiotic resistance.